Suppr超能文献

用右旋糖酐与等渗羟丙基甲基纤维素(HPMC)核黄素溶液治疗的患者的角膜胶原交联:一项回顾性分析。

Corneal collagen crosslinking in patients treated with dextran versus isotonic hydroxypropyl methylcellulose (HPMC) riboflavin solution: a retrospective analysis.

作者信息

Rapuano Patrick B, Mathews Priya M, Florakis George J, Trokel Stephen L, Suh Leejee H

机构信息

Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia College of Physicians and Surgeons, 635 West 165th Street, New York, NY 10032 USA.

出版信息

Eye Vis (Lond). 2018 Sep 10;5:23. doi: 10.1186/s40662-018-0116-z. eCollection 2018.

Abstract

BACKGROUND

Corneal collagen crosslinking (CXL) is a widely used treatment for halting the progression of keratoconus. Although initial studies of CXL were performed with a riboflavin solution containing dextran, recent protocols for CXL have indicated the use of a riboflavin solution containing isotonic hydroxypropyl methylcellulose (HPMC). This study was performed to investigate differences in visual outcomes and Scheimpflug (Pentacam) analysis in patients who have undergone epithelium-off CXL with riboflavin solution containing either 20% dextran versus 1.1% HPMC.

METHODS

All patients in this non-randomized, non-masked, retrospective cohort analysis were treated at Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA. Thirty-seven eyes of 33 patients were crosslinked with a dextran solution and 19 eyes of 19 patients crosslinked with an isotonic HPMC solution, both using an epithelium-off 30-min, 3 mW/cm protocol. All patients had a diagnosis of keratoconus or post-refractive surgery ectasia. Best spectacle corrected visual acuity (BSCVA) and Pentacam parameters were compared at all follow up visits (1, 6, 12, and 24 months). Differences between groups treated with HPMC and dextran were compared using student's t-test. Differences between treated eye and fellow eye were calculated and compared between HPMC and dextran groups using paired t-test.

RESULTS

Patients treated with a dextran solution had significantly greater improvement in BSCVA at 1, 6, and 24 months ( < 0.05) compared to the isotonic HPMC-treated group. Kmax increased in both groups at 1 month; however, HPMC-treated patients had a greater increase compared to dextran-treated patients ( = 0.01). Kmax decreased in both groups at 6 and 12 months, although this finding was only significant in the HPMC-treated group at 12 months.

CONCLUSIONS

Our data suggest that crosslinking with the dextran solution may result in significantly better visual outcomes (demonstrated by visual acuity) compared to the isotonic HPMC riboflavin solution. Dextran solutions may have other potential advantages intrinsic to its biochemical properties facilitating more efficient crosslinking. Further research and long-term evidence regarding the use of dextran versus HPMC riboflavin solutions in collagen crosslinking is necessary.

摘要

背景

角膜胶原交联(CXL)是一种广泛用于阻止圆锥角膜进展的治疗方法。尽管CXL的最初研究是使用含右旋糖酐的核黄素溶液进行的,但最近的CXL方案表明可使用含等渗羟丙基甲基纤维素(HPMC)的核黄素溶液。本研究旨在调查接受使用含20%右旋糖酐或1.1% HPMC的核黄素溶液进行去上皮CXL的患者在视力结果和Scheimpflug(Pentacam)分析方面的差异。

方法

本非随机、非盲、回顾性队列分析中的所有患者均在美国纽约哥伦比亚大学医学中心爱德华·S·哈克尼斯眼科研究所接受治疗。33例患者的37只眼用右旋糖酐溶液进行交联,19例患者的19只眼用等渗HPMC溶液进行交联,均采用30分钟、3 mW/cm²的去上皮方案。所有患者均诊断为圆锥角膜或屈光手术后扩张。在所有随访(1、6、12和24个月)时比较最佳矫正视力(BSCVA)和Pentacam参数。使用学生t检验比较HPMC和右旋糖酐治疗组之间的差异。计算治疗眼与对侧眼之间的差异,并使用配对t检验在HPMC和右旋糖酐组之间进行比较。

结果

与等渗HPMC治疗组相比,使用右旋糖酐溶液治疗的患者在1、6和24个月时BSCVA改善更显著(<0.05)。两组在1个月时Kmax均增加;然而,HPMC治疗的患者比右旋糖酐治疗的患者增加更多(=0.01)。两组在6和12个月时Kmax均下降,尽管这一发现仅在HPMC治疗组12个月时显著。

结论

我们的数据表明,与等渗HPMC核黄素溶液相比,使用右旋糖酐溶液进行交联可能会带来显著更好的视力结果(以视力证明)。右旋糖酐溶液可能因其生化特性具有其他潜在优势,有助于更有效地进行交联。关于在胶原交联中使用右旋糖酐与HPMC核黄素溶液的进一步研究和长期证据是必要的。

相似文献

2
Biomechanical Response After Corneal Cross-linking With Riboflavin Dissolved in Dextran Solution Versus Hydroxypropyl Methylcellulose.
J Refract Surg. 2021 Sep;37(9):631-635. doi: 10.3928/1081597X-20210610-04. Epub 2021 Sep 1.
4
Corneal collagen crosslinking for keratoconus or corneal ectasia without epithelial debridement.
Eye (Lond). 2015 Jun;29(6):764-8. doi: 10.1038/eye.2015.23. Epub 2015 Mar 20.
9
Intraoperative OCT Pachymetry in Patients Undergoing Dextran-Free Riboflavin UVA Accelerated Corneal Collagen Crosslinking.
Curr Eye Res. 2016 Oct;41(10):1310-1315. doi: 10.3109/02713683.2015.1118130. Epub 2016 Feb 16.
10
Six-month outcomes of corneal crosslinking with dextran-free isotonic riboflavin solution.
Arq Bras Oftalmol. 2016 May-Jun;79(3):147-50. doi: 10.5935/0004-2749.20160045.

引用本文的文献

1
Recent advances in medicinal compounds related to corneal crosslinking.
Front Pharmacol. 2023 Sep 29;14:1232591. doi: 10.3389/fphar.2023.1232591. eCollection 2023.

本文引用的文献

3
U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery.
Ophthalmology. 2017 Oct;124(10):1475-1484. doi: 10.1016/j.ophtha.2017.05.036. Epub 2017 Jun 24.
4
United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment.
Ophthalmology. 2017 Sep;124(9):1259-1270. doi: 10.1016/j.ophtha.2017.03.052. Epub 2017 May 7.
5
Corneal collagen crosslinking for corneal ectasias: a review.
Eur J Ophthalmol. 2017 May 11;27(3):253-269. doi: 10.5301/ejo.5000916. Epub 2016 Dec 6.
6
Comparison of Corneal Riboflavin Gradients Using Dextran and HPMC Solutions.
J Refract Surg. 2016 Dec 1;32(12):798-802. doi: 10.3928/1081597X-20160920-03.
7
Is the corneal stromal demarcation line depth a true indicator of corneal collagen crosslinking efficacy?
J Cataract Refract Surg. 2016 May;42(5):804. doi: 10.1016/j.jcrs.2016.02.043.
9
Rate of riboflavin diffusion from intrastromal channels before corneal crosslinking.
J Cataract Refract Surg. 2016 Mar;42(3):462-8. doi: 10.1016/j.jcrs.2015.09.032.
10
Intraoperative OCT Pachymetry in Patients Undergoing Dextran-Free Riboflavin UVA Accelerated Corneal Collagen Crosslinking.
Curr Eye Res. 2016 Oct;41(10):1310-1315. doi: 10.3109/02713683.2015.1118130. Epub 2016 Feb 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验